- Home
- GYRE vs SWIM Comparison
GYRE vs SWIM Comparison
Compare GYRE & SWIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- SWIM
- Stock Information
- Founded
- GYRE 2002
- SWIM 1956
- Country
- GYRE United States
- SWIM United States
- Employees
- GYRE N/A
- SWIM N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- SWIM Plastic Products
- Sector
- GYRE Health Care
- SWIM Industrials
- Exchange
- GYRE Nasdaq
- SWIM Nasdaq
- Market Cap
- GYRE 897.1M
- SWIM 885.7M
- IPO Year
- GYRE N/A
- SWIM 2021
- Fundamental
- Price
- GYRE $7.71
- SWIM $7.79
- Analyst Decision
- GYRE Strong Buy
- SWIM Hold
- Analyst Count
- GYRE 1
- SWIM 3
- Target Price
- GYRE $18.00
- SWIM $6.93
- AVG Volume (30 Days)
- GYRE 86.3K
- SWIM 704.7K
- Earning Date
- GYRE 08-11-2025
- SWIM 08-05-2025
- Dividend Yield
- GYRE N/A
- SWIM N/A
- EPS Growth
- GYRE N/A
- SWIM N/A
- EPS
- GYRE 0.02
- SWIM N/A
- Revenue
- GYRE $102,189,000.00
- SWIM $521,828,000.00
- Revenue This Year
- GYRE $21.04
- SWIM $9.17
- Revenue Next Year
- GYRE $89.64
- SWIM $5.38
- P/E Ratio
- GYRE $454.38
- SWIM N/A
- Revenue Growth
- GYRE N/A
- SWIM N/A
- 52 Week Low
- GYRE $6.11
- SWIM $4.56
- 52 Week High
- GYRE $19.00
- SWIM $8.46
- Technical
- Relative Strength Index (RSI)
- GYRE 49.56
- SWIM 55.21
- Support Level
- GYRE $7.61
- SWIM $8.04
- Resistance Level
- GYRE $8.40
- SWIM $8.46
- Average True Range (ATR)
- GYRE 0.47
- SWIM 0.33
- MACD
- GYRE 0.01
- SWIM -0.02
- Stochastic Oscillator
- GYRE 34.29
- SWIM 37.38
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.